Sanofi-Aventis said it is sticking with an $18.5 billion offer to take over Genzyme, dispelling a rumor that it increased its bid to more than $70 per share to woo the biotech firm's board members. Sanofi CEO Chris Viehbacher met with Genzyme's shareholders this week to pitch the $69-a-share offer, a spokesman said.

Related Summaries